Yoshihiko Taniguchi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Replacement Therapy

Epidermal Growth Factor Receptor

Top Venues

Thoracic cancer

Nature communications

BMJ supportive & palliative care

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshihiko Taniguchi, Akihiro Tamiya, Atsushi Yanagisawa, Minako Shimaya, Mayu Kawakami, Yuji Inagaki, Nobuhiko Saijo, Yoshinobu Matsuda, Kyoichi Okishio
Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report. Thoracic cancer (2023)
Kensuke Kanaoka, Shoich Fukuda, Yuji Inagaki, Yoshihiko Taniguchi, Keiko Nakao, Akihiro Tamiya, Yoshinobu Matsuda, Kyoichi Okishio
Right-sided vocal cord paralysis following stereotactic body radiation therapy for non-small-cell lung cancer: A case report. Thoracic cancer (2023)
Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Koshiro Ohtsubo, Kaname Yamashita, Tomoyoshi Yamano, Akihiro Yoshimura, Koichi Takayama, Kyoichi Kaira, Yoshihiko Taniguchi, Shinji Atagi, Hisanori Uehara, Rikinari Hanayama, Isao Matsumoto, Xujun Han, Kunio Matsumoto, Wei Wang, Takeshi Suzuki, Seiji Yano
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature communications 11 (1) (2020)
Yoshihiko Taniguchi, Akihiro Tamiya, Yoshinobu Matsuda, Yuichi Adachi, Takatoshi Enomoto, Kouji Azuma, Shunichi Kouno, Akihiro Tokoro, Shinji Atagi
Opioids impair Nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. BMJ supportive & palliative care (2020)